Inhibition by red wine extract, resveratrol, of cytokine release by alveolar macrophages in COPD

S V Culpitt, D F Rogers, P S Fenwick, P Shah, C De Matos, R E K Russell, P J Barnes, L E Donnelly

Thorax 2003;58:942–946

Background: The pathophysiology of chronic obstructive pulmonary disease (COPD) features pulmonary inflammation with a predominant alveolar macrophage involvement. Bronchoalveolar macrophages from patients with COPD release increased amounts of inflammatory cytokines in vitro, an effect that is not inhibited by the glucocorticosteroid dexamethasone. Resveratrol (3,5,4'-trihydroxystilbene) is a component of red wine extract that has anti-inflammatory and antioxidant properties. A study was undertaken to determine whether or not resveratrol would inhibit cytokine release in vitro by alveolar macrophages from patients with COPD.

Methods: Alveolar macrophages were isolated from bronchoalveolar lavage (BAL) fluid from cigarette smokers and from patients with COPD (n = 15 per group). The macrophages were stimulated with either interleukin (IL)-1β or cigarette smoke media (CSM) to release IL-8 and granulocyte macrophage-colony stimulating factor (GM-CSF). The effect of resveratrol was examined on both basal and stimulated cytokine release.

Results: Resveratrol inhibited basal release of IL-8 in smokers and patients with COPD by 94% and 88% respectively, and inhibited GM-CSF release by 79% and 76% respectively. Resveratrol also inhibited stimulated cytokine release. Resveratrol reduced IL-1β stimulated IL-8 and GM-CSF release in both smokers and COPD patients to below basal levels. In addition, resveratrol inhibited CSM stimulated IL-8 release by 61% and 51% respectively in smokers and COPD patients, and inhibited GM-CSF release by 49% for both subject groups.

Conclusions: Resveratrol inhibits inflammatory cytokine release from alveolar macrophages in COPD. Resveratrol or similar compounds may be effective pharmacotherapy for macrophage pathophysiology in COPD.
Resveratrol, macrophages and COPD

Royal Brompton and Harefield NHS Trust. Subjects gave informed written consent.

Bronchoalveolar lavage
All subjects were asked to refrain from smoking from the night before BAL fluid sampling (approximately 12 hours). BAL fluid was collected as described previously by sequential instillation and aspiration of 60 ml warmed 0.9% (w/v) normal saline, up to a maximum of 240 ml. Subjects were monitored with digital oximetry.

Isolation and culture of alveolar macrophages
Alveolar macrophages were isolated from the BAL fluid as described previously. The macrophages were resuspended in RPMI-1640 medium containing 10% (v/v) fetal calf serum, 2 mM l-glutamine, 100 iu/ml penicillin, 100 μg/ml streptomycin, and 0.25 μg/ml amphotericin. Cells were seeded in 24-well Falcon cell culture plates (Becton Dickinson, Cowley, Oxfordshire, UK) at a density of 250 000 cells/well and incubated (37°C, 5% CO₂, humidified air) for 2 hours to allow macrophage adherence. The medium was replaced and non-adherent cells removed by aspiration. The macrophages were resuspended in RPMI-1640 medium containing 10% (v/v) fetal calf serum, 2 mM l-glutamine, 100 iu/ml penicillin, 100 μg/ml streptomycin, and 0.25 μg/ml amphotericin. Cells were seeded in 24-well Falcon cell culture plates (Becton Dickinson, Cowley, Oxfordshire, UK) at a density of 250 000 cells/well and incubated (37°C, 5% CO₂, humidified air) for 2 hours to allow macrophage adherence. The medium was replaced and non-adherent cells removed by aspiration. The macrophages were cultured for 24 hours, after which the medium was replaced and cells cultured for a further 24 hours under experimental conditions. Resveratrol and the stimulants were co-administered at time zero. Ten μg/ml IL-1β was used because we have found previously that this concentration gives a consistent stimulation of both IL-8 and GM-CSF release. Cell viability was determined following experimental treatments using trypan blue dye exclusion.

Production of CSM and measurement of endotoxin
CSM was produced as described previously. Smoke from two cigarettes (12 mg tar, 0.9 mg nicotine) was bubbled through 20 ml culture medium and, to ensure standardisation between experiments and batches of CSM, the absorbance was adjusted by dilution to 0.15 at 320 nm using the method of Wirtz and Schmidt. This concentration (nominally 1) is not cytotoxic (see Results below) and was serially diluted with untreated media (0.001- to 1-fold) and applied to the macrophages. The concentration of endotoxin in a 1-fold dilution of CSM was measured using a QCL-1000 endotoxin kit (BioWhittaker, Walkersville, MD, USA) according to the manufacturer’s instructions. The limit of detection of the assay was 0.1 endotoxin unit (EU)/ml.

Cytokine measurements
IL-8 and GM-CSF were measured in macrophage culture supernatants using paired antibody quantitative ELISAs (R&D Systems, Abingdon, Oxfordshire, UK). The lower limit of detection was 15.6 pg/ml for both assays, with a coefficient of variation of 24% for the IL-8 assay and of 17% for the GM-CSF assay. In order to determine whether or not resveratrol affected the cytokine ELISAs, standard curves were constructed in the absence and presence of resveratrol (100 μM).

Statistical analysis
Concentrations of macrophage cytokines between treatment and controls and between COPD patients and smokers were compared using repeated measures analysis of variance (ANOVA). Where differences were found, the minimum value following treatment was taken as a summary measure. The concentration of resveratrol causing 50% inhibition of stimulated cytokine release (IC₅₀ value) was calculated using GraphPad Prism software (GraphPad Software Inc, San Diego, CA, USA). Data are presented as means with 95% confidence intervals (CI) unless stated otherwise.

RESULTS
We have previously reported that there was no difference in the number of inflammatory cells recovered or macrophage number in BAL fluid between the two groups. None of the experimental interventions affected the viability of the macrophages. Resveratrol did not affect the ELISA cytokine measurements; slopes of standard curves for IL-8 were 0.00085 (SE 0.00011) in the absence of resveratrol and 0.00083 (SE 0.00010) in the presence of resveratrol, and for

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Smokers</th>
<th>COPD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>54 (3)</td>
<td>68 (2)**</td>
</tr>
<tr>
<td>Sex (M:F)</td>
<td>11.4</td>
<td>12.3</td>
</tr>
<tr>
<td>Pack years</td>
<td>29 (3)</td>
<td>37 (4)**</td>
</tr>
<tr>
<td>FEV₁ (l)</td>
<td>2.9 (0.2)</td>
<td>1.8 (0.1)***</td>
</tr>
<tr>
<td>FEV₁/FVC</td>
<td>0.84 (0.02)</td>
<td>0.53 (0.03)***</td>
</tr>
</tbody>
</table>

Data are mean (SE). FEV₁ = forced expiratory volume in 1 second; FVC = forced vital capacity. *p<0.05, **p<0.01, ***p<0.001 compared with equivalent value for smokers.

Figure 1  Effect of resveratrol on basal cytokine release by alveolar macrophages from cigarette smokers (□) and patients with COPD (■). Data are presented as mean (SE) concentrations of (A) IL-8 and (B) GM-CSF for 15 subjects in each group. For some data points SE values are within the symbol. ***p<0.001 versus control.

Table 1  Clinical characteristics of healthy smokers and patients with COPD

Table 1: Clinical characteristics of healthy smokers and patients with COPD

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Smokers</th>
<th>COPD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>54 (3)</td>
<td>68 (2)**</td>
</tr>
<tr>
<td>Sex (M:F)</td>
<td>11.4</td>
<td>12.3</td>
</tr>
<tr>
<td>Pack years</td>
<td>29 (3)</td>
<td>37 (4)**</td>
</tr>
<tr>
<td>FEV₁ (l)</td>
<td>2.9 (0.2)</td>
<td>1.8 (0.1)***</td>
</tr>
<tr>
<td>FEV₁/FVC</td>
<td>0.84 (0.02)</td>
<td>0.53 (0.03)***</td>
</tr>
</tbody>
</table>

Data are mean (SE). FEV₁ = forced expiratory volume in 1 second; FVC = forced vital capacity. *p<0.05, **p<0.01, ***p<0.001 compared with equivalent value for smokers.
GM-CSF the values were 0.0011 (SE 0.0001) and 0.0012 (SE 0.0001), respectively.

**Effect of resveratrol on basal cytokine release**
Basal IL-8 release from macrophages was approximately five times greater in patients with COPD than in smokers (262 pg/ml (95% CI 235 to 290) vs 50 pg/ml (95% CI 45 to 57), fig 1A). Resveratrol inhibited basal IL-8 release by macrophages from both smokers (by 94% at 100 μM) and patients with COPD (by 88%, fig 1A). In contrast to IL-8 release, basal release of GM-CSF was similar in the two groups (724 pg/ml (95% CI 686 to 763) vs 737 pg/ml (95% CI 697 to 777), fig 1B). Resveratrol inhibited GM-CSF release by macrophages from smokers and patients with COPD by 79% and 76%, respectively, at 100 μM (fig 1B). There was no significant difference between the IC50 values for inhibition by resveratrol of basal IL-8 or GM-CSF release by macrophages from smokers or patients with COPD (table 2).

**Effect of resveratrol on cytokine release induced by IL-1β**
Exposure of macrophages from smokers or COPD patients to IL-1β (10 ng/ml) increased IL-8 release by 1.8-fold (50 pg/ml (95% CI 45 to 57) vs 87 pg/ml (95% CI 83 to 91)) and 1.3-fold (262 pg/ml (95% CI 235 to 290) vs 328 pg/ml (95% CI 306 to 351)), respectively, above basal values (fig 2A). Similarly, IL-1β increased GM-CSF release by approximately 1.8-fold above basal values in both groups (737 pg/ml (95% CI 697 to 777) vs 1327 pg/ml (95% CI 1223 to 1431) and 724 pg/ml (95% CI 686 to 763) vs 1548 pg/ml (95% CI 1448 to 1547), respectively; fig 2B). Resveratrol inhibited IL-1β stimulated IL-8 release and GM-CSF release by macrophages from both smokers and patients with COPD to below their respective basal levels (fig 2A and B). There was no significant difference in IC50 values for inhibition by resveratrol of IL-1β stimulated IL-8 or GM-CSF release by macrophages from smokers and patients with COPD (table 2).

**Effect of resveratrol on cytokine release induced by CSM**
Exposure of macrophages from smokers or patients with COPD to CSM (1 fold dilution) increased IL-8 release by ~3-fold (50 pg/ml (95% CI 45 to 57) vs 141 pg/ml (95% CI 128 to 154)) and ~2-fold (262 pg/ml (95% CI 235 to 290) vs 542 pg/ml (95% CI 518 to 265)), respectively, above basal values (fig 3A). Similarly, CSM increased GM-CSF release by ~2-fold (737 pg/ml (95% CI 697 to 777) vs 1493 pg/ml (95% CI 1398 to 1587)) and 2.7-fold (724 pg/ml (95% CI 686 to 763) vs 1977 pg/ml (95% CI 1873 to 2081)) above basal values in smokers and COPD patients, respectively (fig 3B). The concentration of endotoxin in the CSM was below the level of detection of the assay (~0.1 EU/ml).

Resveratrol inhibited CSM stimulated IL-8 release by macrophages from smokers and patients with COPD by 61% and 51%, respectively (fig 3A). Similarly, resveratrol inhibited GM-CSF release by macrophages from smokers to basal levels and by macrophages from COPD patients by 49% (fig 3B). There was no significant difference between the IC50 values for inhibition by resveratrol of CSM stimulated IL-8 and GM-CSF release by macrophages from smokers and patients with COPD (table 2).

**DISCUSSION**
IL-1β or CSM stimulated cytokine release by BAL fluid alveolar macrophages from cigarette smokers and COPD patients, effects which have been described previously by us7 and by others.26 The increased basal levels of IL-8 release by macrophages from patients with COPD seen here are unlikely to be due to inhaled bronchodilator medication because β2 adrenoceptor agonists inhibit rather than stimulate cytokine release from differentiated U937 human macrophage-like cells27 while acetylcholine stimulates cytokine release from bovine alveolar macrophages,28 an effect that would be counteracted by ipratropium bromide, leading to decreased cytokine levels. CSM stimulation of cytokine release is unlikely to be due to the presence of endotoxin in the CSM because

---

**Table 2** Inhibition by resveratrol of basal or stimulated cytokine release from alveolar macrophages

<table>
<thead>
<tr>
<th>Stimulus</th>
<th>Cytokine</th>
<th>Smokers</th>
<th>COPD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basal</td>
<td>IL-8</td>
<td>7.4 (0.4)</td>
<td>6.9 (0.4)</td>
</tr>
<tr>
<td></td>
<td>GM-CSF</td>
<td>7.0 (0.1)</td>
<td>6.8 (0.1)</td>
</tr>
<tr>
<td>IL-1β</td>
<td>IL-8</td>
<td>6.7 (0.1)</td>
<td>6.2 (0.4)</td>
</tr>
<tr>
<td></td>
<td>GM-CSF</td>
<td>6.9 (0.2)</td>
<td>6.9 (0.3)</td>
</tr>
<tr>
<td>CSM</td>
<td>IL-8</td>
<td>6.4 (0.3)</td>
<td>7.4 (1.2)</td>
</tr>
<tr>
<td></td>
<td>GM-CSF</td>
<td>7.1 (0.3)</td>
<td>6.7 (0.2)</td>
</tr>
</tbody>
</table>

COPD = chronic obstructive pulmonary disease; CSM = cigarette smoke medium; IL = interleukin; GM-CSF = granulocyte macrophage-colony stimulating factor.

Values are mean (SE) IC50 values expressed as –log [resveratrol] (M) (n = 15 per group).

---

**Figure 2** Effect of resveratrol on IL-1β stimulated cytokine release by alveolar macrophages from smokers (□) and patients with COPD (■). Data are mean (SE) concentrations of (A) IL-8 or (B) GM-CSF for 15 subjects in each group. For some data points SE values are within the symbol. **p<0.001 versus control (IL-1β stimulated, 10 ng/ml); ordinate is split in panel A. The dashed line is the basal value for smokers and the dotted line is the basal value for patients with COPD.
endotoxin was not detected in the media. With reference to the validity of comparison of the effects of CSM in vitro to in vivo cigarette smoke exposure, the relationship between CSM and exposure of macrophages to cigarette smoke in vivo is not known. However, in rats CSM and cigarette smoke in vivo induce similar patterns of DNA damage. Although not measured specifically in the present study, differences in BAL fluid cytokine and inflammatory mediator concentrations between patients with COPD and smoking controls may influence subsequent macrophage responses.

We found that resveratrol inhibited both basal and stimulated cytokine release by BAL fluid macrophages from cigarette smokers and patients with COPD. This is consistent with the inhibitory effects of resveratrol in a variety of cell preparations, including macrophages. For example, resveratrol inhibited IL-12 and TNFα release and IL-6 release by murine peritoneal macrophages. It is noteworthy that, in the present study, the inhibition of cytokine release by resveratrol was similar for both IL-8 and GM-CSF and for both subject groups, as evidenced by the IC₅₀ values (table 2). The mechanism of the inhibition by resveratrol of cytokine release is not explored in the present study. However, inhibition of cytokine release may be due to suppression of NF-kB and AP-1 activation, with a consequent reduction in inflammatory cytokine expression. Suppression of NF-kB may involve a decrease in the phosphorylation and, hence, degradation of IκBα. For the inhibition of CSM induced cytokine release, resveratrol is an antioxidant and an antagonist for the receptor for aryl hydrocarbons which are found in cigarette smoke. These properties would both be consistent with inhibition of CSM induced responses.

We have previously found that the glucocorticosteroid dexamethasone did not inhibit IL-8 release by BAL fluid macrophages from patients with COPD. This is in contrast to the marked inhibition observed in the present study by resveratrol in these same patient groups. In particular, resveratrol inhibited CSM stimulated GM-CSF release from both patient groups, whereas dexamethasone had no inhibitory effect except at a high concentration (10 µM) in smokers. The reasons underlying these apparent differential inhibitory effects of resveratrol and dexamethasone are unclear, but may be due to the antioxidant properties of resveratrol in addition to its anti-inflammatory activity.

Current treatment for the lung inflammation in stable COPD is suboptimal, with clinical use of glucocorticosteroids being controversial. Any lack of corticosteroid efficacy could be the result of reduced steroid sensitivity by pulmonary macrophages. In the present study we found that resveratrol inhibits basal and stimulated cytokine release by BAL macrophages in COPD patients. Specifically, resveratrol inhibited release of the neutrophil chemotactic factor IL-8 and the cell survival cytokine GM-CSF. This could lead to inhibition of neutrophilia and decreased levels of inflammatory cytokines in the airways of patients with COPD. Thus, resveratrol or related compounds may be more effective pharmacotherapeutic compounds than corticosteroids for the treatment of chronic stable COPD. A possible clinical disadvantage of resveratrol is its low bioavailability. Consequently, resveratrol analogues such as picatanol are under investigation.

ACKNOWLEDGEMENTS
This study was supported by a Training Fellowship from the Medical Research Council, UK (SVC), Bayer plc, Stoke Poges, UK (CDM), and the British Lung Foundation (REKR).

Authors’ affiliations
S V Culpitt, D F Rogers, P S Fenwick, P Shah, C De Matos, R E K Russell, P J Barnes, L E Donnelly, Department of Thoracic Medicine, National Heart & Lung Institute, Imperial College London, London SW3 6LY, UK

REFERENCES


Inhibition by red wine extract, resveratrol, of cytokine release by alveolar macrophages in COPD

S V Culpitt, D F Rogers, P S Fenwick, P Shah, C De Matos, R E K Russell, P J Barnes and L E Donnelly

Thorax 2003 58: 942-946
doi: 10.1136/thorax.58.11.942

Updated information and services can be found at:
http://thorax.bmj.com/content/58/11/942

These include:
References
This article cites 32 articles, 5 of which you can access for free at:
http://thorax.bmj.com/content/58/11/942#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Health education (1223)
Smoking (1037)
Tobacco use (1039)
Inflammation (1020)
Pneumonia (infectious disease) (579)
Pneumonia (respiratory medicine) (562)
TB and other respiratory infections (1273)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/